June 16 | 2020
2cureX AB establishes collaboration with Scandion Oncology A/S and Erasmus Medical Centre, Rotterdam, in drug-resistant breast cancer patients
Read more
June 16 | 2020
2cureX AB establishes collaboration with Scandion Oncology A/S and Erasmus Medical Centre, Rotterdam, in drug-resistant breast cancer patients
Read more
May 29 | 2020
2cureX moves forward with the commercialization of IndiTreat by signing a new distributor agreement in Portugal
Read more
May 29 | 2020
2cureX moves forward with the commercialization of IndiTreat by signing a new distributor agreement in Portugal
Read more
April 6 | 2020
2cureX, Germany receives an additional grant for adapting IndiTreat® to guide immunotherapy of ovarian cancer patients
Read more
April 6 | 2020
2cureX i Tyskland får bidrag för att anpassa IndiTreat® för vägledning av immunterapi mot äggstockscancer
Read more
April 2 | 2020
2cureX establish clinical partnership with Skåne University Hospital, Sweden
Read more
April 2 | 2020
2cureX inleder kliniskt partnerskap med Skånes universitetssjukhus
Read more
March 23 | 2020
2cureX provides update regarding the COVID-19 impact on ongoing clinical programs
Read more
March 23 | 2020
2cureX provides update regarding the COVID-19 impact on ongoing clinical programs
Read more
March 6 | 2020
2cureX is accelerating the commercialization of IndiTreat® by signing two distributor agreements to prepare for launch in second half of 2020
Read more
March 6 | 2020
2cureX ökar takten i kommersialiseringen av IndiTreat® – tecknar två nya distributörsavtal inför lansering andra halvan av 2020
Read more
February 28 | 2020
2cureX offentliggör bokslutskommuniké för räkenskapsåret 2019
Read more
February 28 | 2020
2cureX publishes year-end report for 2019
Read more
January 6 | 2020
2cureX continues its IP expansion by securing a patent on its IndiTreat test in Australia
Read more
January 6 | 2020
2cureX fortsätter sin IP-expansion genom att säkra ett patent på sitt IndiTreat-test i Australien
Read more
December 13 | 2019
2cureX presenterar framsteg i analysutveckling för IndiTreat® i immuno-onkologi vid ESMO Immuno-Oncology Congress i Genève 11-14 december 2019.
Read more
December 13 | 2019
2cureX presented progression in the IndiTreat® immuno-oncology assay development at the ESMO Immuno-Oncology Congress in Geneva 11-14 Dec. 2019.
Read more